E98: Key Opinion Leaders & ILD Guidelines

FromThe Evidence Based Rheumatology Podcast

Start listening View podcast show

E98: Key Opinion Leaders & ILD Guidelines

FromThe Evidence Based Rheumatology Podcast

ratings:

Length:

10 minutes

Released:

Aug 24, 2023

Format:

Podcast episode

Description

Podcast this week discussing key opinion leaders (KOLs) and pharmaceutical companies. Please subscribe to my newsletter (ebrheum.com) and be sure to share the podcast with friends!

Released:

Aug 24, 2023

Format:

Podcast episode

Titles in the series (87)

A weekly podcast for physicians interested in evidence based medicine and rheumatology. Find the papers at ebrheum.com

Skip carousel

E17: Steroids and the Risk of Scleroderma Renal Crisis: Short but impactful paper this week on the association between steroids and scleroderma renal crisis. Find the original paper here. by The Evidence Based Rheumatology Podcast
11 min listen
E6: Methylprednisolone and Cyclophosphamide, Alone or in Combinatinon, for Lupus Nephritis: Welcome back! Before we talk about cellcept for lupus nephritis, I decided we should flash back to 1996 and discuss one of the early trials that brought us cyclophosphamide. It's a quick discussion that will help set us up nicely for ALMS this Sunday. ... by The Evidence Based Rheumatology Podcast
9 min listen
E13: Withdrawing HCQ in SLE: Short podcast today on an old RCT addressing the utility of hydroxychloroquine (plaquenil) in lupus. It's an oldie but goodie and one that I enjoyed talking about. by The Evidence Based Rheumatology Podcast
11 min listen
E22: Ustekinumab for Giant Cell Arteritis: Quick episode today on a small prospective trial on ustekinumab for giant cell arteritis. Papers can all be found here! by The Evidence Based Rheumatology Podcast
9 min listen
E9: Rituximab in Myositis - The RIM Trial: This week we'll discuss a randomized controlled-ish trial, the RIM study. It pits rituximab against placebo as well as... rituximab? We'll talk about how their design convincingly demonstrated that ritixan does not have a benefit over placebo for 8 week... by The Evidence Based Rheumatology Podcast
17 min listen
E14: Cardiovascular Safety of Febuxostat: Today we'll discuss an important trial on febuxostat (ulloric), which raises important concerns about its safety from a cardiovascular perspective. Be sure to tune in to the #RheumJC discussion that will be happening this Thursday! by The Evidence Based Rheumatology Podcast
14 min listen
E46: Rituximab in Lupus: Finally got around to tackling rituximab in SLE. This is a tough topic: lots of people feel passionately one way or another, flawed observational data supports its use, flawed RCTs did not find significant benefit, and patients are left in the lurch. I... by The Evidence Based Rheumatology Podcast
22 min listen
E16: Tocilizumab in Giant-Cell Arteritis - GIACTA: Getting back to our usual format, this week we'll discuss the GIACTA trial, which compared various schedules of tocilizumab to various schedules of placebo and prednisone. It's an important trial that has changed the face of GCA and will be a refreshing... by The Evidence Based Rheumatology Podcast
16 min listen
E8: Mepolizumab or Placebo for EGPA: This week we'll discuss a recent trial on mepolizumab - and IL-5 inhibitor - for eosinophilic granulomatosis with polyangiitits. Find the paper here and be sure to follow us on twitter @JBRheum! by The Evidence Based Rheumatology Podcast
14 min listen
E12: ACR 2015 Workforce Study - the Rheumageddon!: This week we'll discuss the recently published ACR Workforce Study, which estimates a substantial deficit in the workforce by 2030. We'll consider how dire the situation actually is - checkout the paper itself here. by The Evidence Based Rheumatology Podcast
15 min listen
E10: Abatacept in RA-ILD: Quick podcast tonight reflecting the Rheumatology Journal Club (@RheumJC) discussion! I joined as they discussed the use of abatacept in patients with rheumatoid arthritis who develop ILD. It's our first observational trial, so it's ripe for critique! F... by The Evidence Based Rheumatology Podcast
13 min listen
E92: Are muscle symptoms from statins imaginary?: Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! Paper: https://www.thelancet.com/arti... by The Evidence Based Rheumatology Podcast
11 min listen
E44: SELECT-COMPARE Upadacitinib (JAKi) for Rheumatoid Arthritis: Finally got around to tackling the JAKi this week. I decided to focus on SELECT-COMPARE, which pitted upadacitinib (selective JAK1 inhibitor) against adalimumab and placebo. I briefly discuss other JAKs and my thoughts on the future of this area. Get t... by The Evidence Based Rheumatology Podcast
10 min listen
E26: Housekeeping 1: Every 25 episodes I'd like to step back and touch base about where the podcast is headed. Thanks to everyone who has been listening! Apologies for nothing exciting or useful this week. by The Evidence Based Rheumatology Podcast
4 min listen
E7: The ALMS Trial - MMF vs CYC for Lupus Nephritis: Today we'll be discussing the ALMS trial, which pitted cellcept against cyclophosphamide. It's a good trial that has had profound influences on our practice and well worth a read. Access the paper itself here. by The Evidence Based Rheumatology Podcast
10 min listen
E25: MAINRITSAN 2 - Fixed vs. Tailored Rituxan for AAV: Interesting trial this week evaluating a fixed schedule of rituximab vs. a tailored approach to therapy. See you all at ACR this week! by The Evidence Based Rheumatology Podcast
12 min listen
E42: SENSCIS - Nintedanib for Systemic Sclerosis ILD: This week I'll discuss an important paper in systemic sclerosis, the recent SENSCIS trial that compared 150mg nitedanib to placebo. I wind up coming down pretty hard on this drug; I think it's hype has vastly outpaced its utility. Get the paper itself a... by The Evidence Based Rheumatology Podcast
16 min listen
E45: TNF or TCZ or ABA or RTX: Real World Data for RA: This week I tackle an interesting cohort study that Jack Cush (@RheumNow) mentioned in his podcast. It's a nice opportunity to discuss bDMARDs in the "real world" (AKA Sweden). Follow me @ebrheum and let me know what you think of the episode! by The Evidence Based Rheumatology Podcast
15 min listen
E19: Clinical Utility of a Positive ANA: Quick podcast this week on the utility of an ANA. It's a frequent reason for referral (17% in this series) to rheumatology offices and this is a useful paper for context. Find the paper itself here. by The Evidence Based Rheumatology Podcast
8 min listen
E54: Rheum4Debate - Triple Tx is 1st Line in RA w/No Response to MTX: Happy New Year! This week Dr. Anisha Dua (@anisha_dua) and Dr. Sarah Fantus (@sarahfantus) debate this motion: "In MTX non-responders with RA, triple therapy (adding HCQ & SSZ) should be first line." Please be sure to VOTE AGAIN on twitter (@ebrheum) a... by The Evidence Based Rheumatology Podcast
17 min listen
E36: Baricitinib for SLE: This week I discuss the phase 2 trial on baricitinib in SLE. Though it's early times (and the total flop of rituxan in ME/CFS recently can attest to this), this was a large phase 2 and I'm hopeful it carries through to the ongoing phase 3 trials. Follo... by The Evidence Based Rheumatology Podcast
14 min listen
E31: SEAM and MIPA Trials: MTX vs. ETN for Psoriatic Arthritis: This week we tackle two RCTs and try to figure out what to do with etanercept, methotrexate, and placebo (or the lack thereof). Good opportunity for jumping into more PsA trials in the near future - lots of IL-somethings to talk about! Remember to foll... by The Evidence Based Rheumatology Podcast
13 min listen
E23: Stress Related Disorders and Subsequent Autoimmune Disease: Great article this week on stress related disorders and their relationship with subsequent autoimmune disease. One of my favorite recent papers from my least favorite way to do a study! Remember, all my articles can be found here! by The Evidence Based Rheumatology Podcast
18 min listen
E15: The Ribosomal P Isn't Useful in NPSLE by The Evidence Based Rheumatology Podcast
17 min listen
E28: Nurse Run Treat to Target vs. Usual Care? in Gout: Interesting trial this week pitting an elaborate nurse led group against suboptimal usual care. Suboptimal usual care lost pretty badly, but what to make of this? And does it support the rheumatologist side of the treat to target controversy? Listen t... by The Evidence Based Rheumatology Podcast
15 min listen
E66: MRI to Diagnose PMR: Great paper to discuss this week - one that may be too good to believe? I highly recommend checking out the pdf first (ebrheum.com/twts) - their graphics are wonderful and do a great job of conveying their message. Also, check out the "2-5-10" rule that... by The Evidence Based Rheumatology Podcast
14 min listen
E55: Anifrolumab for SLE (TULIP 1&2): This week I talk about the recently published TULIP 1 and TULIP 2 trials that assessed anifrolumab for active SLE. Great to see a new drug in this disease state; interesting to think through how these trials played out. Get the papers and the pod at eb... by The Evidence Based Rheumatology Podcast
18 min listen
E37: TRACE-RA Atorvastatin for Primary Prevention of CVD in RA: This week I pair the recently published TRACE-RA trial assessing the efficacy of atorvastatin in primary prevention of cardiovascular disease. It offered a great opportunity to also go after the recent Nature publication "Scientists rise up against stati... by The Evidence Based Rheumatology Podcast
18 min listen
E79: Vasculitis Guidelines E5 - GCA with Dr. Mehrdad Maz: On today's episode I discuss GCA with Dr. Mehrdad Maz. He is the Division Director of the Kansas University Allergy, Clinical Immunology and Rheumatology Section and served on the Steering Core Committee of the ACR-VF Vasculitis Treatment Guidelines. We... by The Evidence Based Rheumatology Podcast
27 min listen
E52: HOPE RCT - Prednisone for OA of the Hand: Surprising RCT this week discussing the HOPE trial, which pitted 10mg prednisone against placebo for inflammatory hand OA. I do think this will change my practice, but in a far narrower sense than the headline would suggest. Check it out and find all my ... by The Evidence Based Rheumatology Podcast
9 min listen

More Episodes from The Evidence Based Rheumatology Podcast

Skip carousel

E111: PEXIVAS Subsets with Mike Walsh & Mats Junek: At ACR23 I had a twitter-disagreement about steroid tapers from PEXIVAS with Mike Walsh, the lead author on the PEXIVAS trial. He kindly agreed to join me for a moderated discussion. Loved hearing his perspective and have to admit he pulled me closer... by The Evidence Based Rheumatology Podcast
39 min listen
E110: Rheum4Debate - Screening for RA-ILD with Joshua Solomon and Scott Matson: Rheum4Debate is back! In this episode I moderated a debate between two pulmonologists about RA-ILD. As a reminder, Rheum4Debate is an Oxford-style debate show, where two debators disagree over a motion during 3 rounds of discussion. The motion for to... by The Evidence Based Rheumatology Podcast
24 min listen
E109: Abatacept for Pre-RA - the ARIAA Study: Nice study this week on an important topic. Can we prevent the development of rheumatoid arthritis by initiating DMARDs during a preclinical phase? Lots to discuss: what does it mean to be "pre-clinical?" How does this fit with other studies of this ... by The Evidence Based Rheumatology Podcast
16 min listen
E108: Myositis Guidelines for Cancer Screening w/Alexander Oldroyd: Informative podcast this week with Dr. Alexander Oldroyd, the first author of the recently published "International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening." The article itself appeared in Nature Reviews Rheumatolog... by The Evidence Based Rheumatology Podcast
16 min listen
E107: Fragility of SLE Randomized Controlled Trials: Quick methodology episode this week discussing the concept of "fragility" in randomized controlled trials of lupus. Really enjoyed discussing this paper and was grateful to have been a part of it. Get the text here: https://lupus.bmj.com/content/lupu... by The Evidence Based Rheumatology Podcast
13 min listen
E106: GCA/PMR with Bhaskar Dasgupta: Today I'm taking another twitter discussion into the podcast realm! Dr. Bhaskar Dasgupta has published hundreds of papers about polymyalgia rheumatica and giant cell arteritis, including a recent publication in Nature Reviews: Rheumatology that pique... by The Evidence Based Rheumatology Podcast
28 min listen
E105: Autoimmunity Post COVID-19?: Interesting topic and interesting paper this year, including discussion of observational biases, positive and negative controls, and interpreting data as it comes. Paper: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2810259 by The Evidence Based Rheumatology Podcast
18 min listen
E104: Sarilumab for PMR - The SAPHYR Study: Important trial on the podcast this week! I take a deep dive into the recently published SAPHYR study, which evaluated the use of the IL6 inhibitor sarilumab for patients with PMR. A few aggravating quibbles but overall a very useful trial and an imp... by The Evidence Based Rheumatology Podcast
19 min listen
E103: Len Calabrese on Monoclonal Antibodies for COVID-19: This week I took a twitter disagreement from the impersonal world of twitter to the podcast world of a back and forth conversation. Really enjoyed talking to Dr. Len Calabrese about monoclonal antibodies, FDA regulatory pathways, and life in general.... by The Evidence Based Rheumatology Podcast
22 min listen
E102: Unintentional Unblinding in Rheumatic Disease Trials: Excited to share an editorial that I wrote along with Cody Bruggemeyer and Desh Nepal, two trainees with me at the Medical College of Wisconsin. We discussed what I believe to be a pervasive (but seldom discussed) issue in rheumatology RCTs: unblindi... by The Evidence Based Rheumatology Podcast
12 min listen
E101: Pred v Colchicine for CPPD: COLCHICORT: Happy to share the FIRST randomized trial in CPPD today. It's kind of a weird study but worth a quick discussion. https://www.sciencedirect.com/science/article/pii/S2665991323001650 by The Evidence Based Rheumatology Podcast
11 min listen
E100: ADVOCATE Health Related Quality of Life: This week I dive into the health related quality of life measures that were reported in the ADVOCATE study. I found them overall somewhat convincing and they have affected my practice. Have a listen and be sure to follow along. Find my work at ebrheu... by The Evidence Based Rheumatology Podcast
16 min listen
E99: Hospital Problems: Quick episode this week from a recent Perspective piece I had published in the New England Journal. Have a listen or a read! https://www.nejm.org/doi/full/10.1056/NEJMp2304828 by The Evidence Based Rheumatology Podcast
7 min listen
E97: Does allopurinol reduce CVD? The ALLHEART Study: Nice quick RCT rundown this week, covering the ALLHEART study, a pragmatic RCT of urate lowering therapy to reduce cardiovascular disease. Quick listen for a useful teaching point! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)0... by The Evidence Based Rheumatology Podcast
10 min listen
E96: Long COVID - Where to After Norway?: Today I cover the recently published long-COVID study from Norway. It's a great paper that challenges much of the prevailing wisdom. I think there are some interesting limitations, but anyone who sees post COVID patients (aka all of us) would do well... by The Evidence Based Rheumatology Podcast
20 min listen
E95: Rituximab or Cyclophosphamide in ANCA Vasculitis: Fun study this week from JAMA Network Open and the French Vasculitis Study Group. They used a target trial emulation (one of my favorites) to ask whether RTX > CYC in AAV (another one of my favorites). I tried to use this to compare between observati... by The Evidence Based Rheumatology Podcast
21 min listen
E94: Steroids and Psoriasis Flares by The Evidence Based Rheumatology Podcast
8 min listen
E93: Azathioprine is the Worst: Today I'll be reading one of my recent newsletters! It's kind of a fun run-down of my anti-azathioprine stance. As I say in the piece, some patients may benefit from azathioprine and I am not saying it is an entirely useless drug or that nobody shoul... by The Evidence Based Rheumatology Podcast
7 min listen
E92: Are muscle symptoms from statins imaginary?: Today I review a recent large meta analysis of randomized controlled trials of statin use. Super interesting findings that have changed my clinical practice. Check out the paper here and listen to the episode! Paper: https://www.thelancet.com/arti... by The Evidence Based Rheumatology Podcast
11 min listen
E91: Clinical Innovation in Rheumatology: Past, Present, and Future: Change of pace today! I interviewed Jason Liebowitz and Phil Seo about their new book entitled "Clinical Innovation in Rheumatology: Past, Present, and Future." I thoroughly enjoyed the book and had a great time interviewing them about some of their ... by The Evidence Based Rheumatology Podcast
20 min listen
E90: There Is No Diagnosis of Exclusion in Rheumatology: Quick episode this week to share an editorial I recently wrote with Jay Patel and Anisha Dua. We cover one of my least phrases in medicine, the "diagnosis of exclusion." Hope you enjoy! Find the original paper here: https://academic.oup.com/rheuma... by The Evidence Based Rheumatology Podcast
7 min listen
E89: Vitamin D to Prevent Osteoporotic Fractures: Exciting (negative) results from a large RCT on the podcast this week as well as a (mini) rant about how we should be spending our time as rheumatologists and the false security of ineffective treatments. Let me know what you think on twitter @ebhru... by The Evidence Based Rheumatology Podcast
11 min listen
E88: HCQ Dose Reductions and SLE Flares: Interesting case-crossover study today evaluating the association between HCQ dosing and risk of SLE flares. Super worth your time to read the paper or listen to this episode! https://jamanetwork.com/journals/jama/article-abstract/2796634 by The Evidence Based Rheumatology Podcast
10 min listen
E87: IVIG for Dermatomyositis: Podcast is back! This week I discuss a pivotal RCT in dermatomyositis. Check it out and be sure to subscribe to my newsletter at ebrheum.com! by The Evidence Based Rheumatology Podcast
18 min listen
E86: Target Trials and Causality in Rheumatology: Mixing it up again this week to discuss an editorial by Miguel Hernan and a systematic review of target trials in rheumatology. It's kind of a fun free-form stream of consciousness. Hope you enjoy! Links: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5... by The Evidence Based Rheumatology Podcast
16 min listen
E85: Challenging Wisely: Quick episode today. I wanted to share an editorial that was recently published in Rheumatology, where I and co-authors (Shannon Tai and Natalie Anumolu) discuss lessons from recent trials in AAV and SLE. Link to editorial: https://pubmed.ncbi.nlm.nih... by The Evidence Based Rheumatology Podcast
8 min listen
E84: The JAKapocalypse (AKA ORAL Surveillance) by The Evidence Based Rheumatology Podcast
12 min listen
E83: Effectiveness of COVID-19 Vaccines: After a winter hiatus, the podcast is back! Today I wanted to dive into a 'hotbutton' issue - the question of whether (or not) COVID-19 vaccines "work" for patients with rheumatic diseases. My answer is an emphatic "yes," albeit with a few caveats. Here ... by The Evidence Based Rheumatology Podcast
19 min listen
E82: LoVAS Trial for ANCA Vasculitis: Hello again! Snappy episode this week about the exciting LoVAS trial, which compared a reduced dose steroid taper for ANCA vasculitis. Be sure to drop by my website at ebrheum.com to subscribe to my newsletter! by The Evidence Based Rheumatology Podcast
15 min listen
E81: Vasculitis Guidelines E7: Takayasu Arteritis with Dr. Andy Abril: In this episode, I talk with Dr. Andy Abril, Chair at the Division of Rheumatology at the Mayo Clinic in Jacksonville Florida. Dr. Abril is one of the lead authors for the 2021 ACR Guidelines on Takayasu’s arteritis. This project was done in partnershi... by The Evidence Based Rheumatology Podcast
21 min listen

Discover this podcast and so much more

E98: Key Opinion Leaders & ILD Guidelines

E98: Key Opinion Leaders & ILD Guidelines

Description

Titles in the series (87)

More Episodes from The Evidence Based Rheumatology Podcast